Literature DB >> 9428445

Prognostic factors in idiopathic membranous nephropathy.

L J Reichert1, R A Koene, J F Wetzels.   

Abstract

Membranous nephropathy is the most frequent cause of glomerulonephritis in adults with nephrotic syndrome. Approximately one quarter of the patients develop end-stage renal disease. Another quarter enters complete remission during follow-up. Treating all patients with membranous nephropathy with immunosuppressive drugs would unnecessarily expose at least one quarter of the patients to these toxic drugs. Identifying patients at highest risk would allow tailor-made treatment. Many risk factors have been found, such as male sex, HLA type DR3+/B8+, white race, advanced age, and tubulointerstitial changes or focal sclerosis found with renal biopsy. In addition, nephrotic syndrome, elevation of immunoglobulin G excretion or beta2-microglobulin excretion, low serum albumin, high serum cholesterol, an elevation of urinary excretion of complement activation products, impaired renal function at diagnosis, and, finally, hypertension are associated with a higher risk of renal function deterioration during follow-up. We have critically reviewed the literature and summarized the clinical significance of the above-mentioned risk factors in predicting subsequent renal function deterioration in patients with membranous nephropathy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9428445     DOI: 10.1053/ajkd.1998.v31.pm9428445

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  26 in total

1.  Prognostic value of risk score and urinary markers in idiopathic membranous nephropathy.

Authors:  Jan A J G van den Brand; Julia M Hofstra; Jack F M Wetzels
Journal:  Clin J Am Soc Nephrol       Date:  2012-05-17       Impact factor: 8.237

2.  Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria.

Authors:  Eduardo F Borba; Lissiane K Guedes; Romy B Christmann; Camille P Figueiredo; Célio R Gonçalves; Eloisa Bonfá
Journal:  Rheumatol Int       Date:  2006-05-31       Impact factor: 2.631

3.  Serum uric acid is an independent predictor of renal outcomes in patients with idiopathic membranous nephropathy.

Authors:  Ji Zhang; Min Pan; JianNa Zhang; XiaoHan You; Dou Li; Fan Lin; GuoYuan Lu
Journal:  Int Urol Nephrol       Date:  2019-08-28       Impact factor: 2.370

4.  Relapse and its remission in Japanese patients with idiopathic membranous nephropathy.

Authors:  Shinji Kitajima; Kengo Furuichi; Norihiko Sakai; Akihiro Sagara; Yasuyuki Shinozaki; Tadashi Toyama; Yasunori Iwata; Miho Shimizu; Hitoshi Yokoyama; Shuichi Kaneko; Takashi Wada
Journal:  Clin Exp Nephrol       Date:  2014-06-24       Impact factor: 2.801

5.  Low-molecular-weight proteins as prognostic markers in idiopathic membranous nephropathy.

Authors:  Jan A J G van den Brand; Julia M Hofstra; Jack F M Wetzels
Journal:  Clin J Am Soc Nephrol       Date:  2011-12       Impact factor: 8.237

Review 6.  Treatment of idiopathic membranous nephropathy.

Authors:  Julia M Hofstra; Fernando C Fervenza; Jack F M Wetzels
Journal:  Nat Rev Nephrol       Date:  2013-07-02       Impact factor: 28.314

7.  Association of phospholipase A2 receptor 1 polymorphisms with idiopathic membranous nephropathy in Chinese patients in Taiwan.

Authors:  Yu-Huei Liu; Cheng-Hsu Chen; Shih-Yin Chen; Ying-Ju Lin; Wen-Ling Liao; Chang-Hai Tsai; Lei Wan; Fuu-Jen Tsai
Journal:  J Biomed Sci       Date:  2010-10-11       Impact factor: 8.410

Review 8.  Membranous nephropathy in the older adult: epidemiology, diagnosis and management.

Authors:  Jeroen K J Deegens; Jack F M Wetzels
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

9.  Membranous glomerulonephritis: treatment response and outcome in children.

Authors:  Rudolph P Valentini; Tej K Mattoo; Gaurav Kapur; Abubakr Imam
Journal:  Pediatr Nephrol       Date:  2008-10-10       Impact factor: 3.714

Review 10.  Membranous nephropathy in children: clinical presentation and therapeutic approach.

Authors:  Shina Menon; Rudolph P Valentini
Journal:  Pediatr Nephrol       Date:  2009-11-12       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.